Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 42 Carcinoma, Non-Small-Cell Lung 18 Neoplasms 15 Neoplasm Metastasis 14 Carcinoma, Renal Cell 10 Carcinoma, Hepatocellular 8 Ovarian Neoplasms 6 Colorectal Neoplasms 6 Uveal Melanoma 5 Triple Negative Breast Neoplasms 5 Small Cell Lung Carcinoma 5 Pancreatic Neoplasms 5 Mesothelioma 5 Diabetes Mellitus, Insulin-Dependent, 12 5 Carcinoma, Transitional Cell 5 Squamous Cell Carcinoma of Head and Neck 4 Sarcoma 4 Lung Neoplasms 4 Carcinoma, Merkel Cell 4 Advanced Cancer 4 Uterine Cervical Neoplasms 3 Stomach Neoplasms 3 Prostatic Neoplasms 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Lymphoma 3 Liver Neoplasms 3 Hodgkin Disease 3 Head and Neck Neoplasms 3 Carcinoma 3

Interventions

tocilizumab 1 selicrelumab 1 niraparib 1 durvalumab 1 cobimetinib 1 atezolizumab 1 Tiragolumab 1 Panitumumab 1 PEGPH20 1 Oxaliplatin 1 Optical Imaging 1 Nivolumab 1 Leucovorin 1 Ipilimumab 1 Gemcitabine 1 Fluorouracil 1 Bevacizumab 1 4-fluorobenzoyl-TN-14003 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Pancreatic Adenocarcinoma × Ipilimumab × Clear all

NCT03404960 2025-10-10

Parpvax

University of Pennsylvania

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡